Amyris Named Gold 2016 Edison Award Winner -- One of Highest Accolades for Innovation in Business

Recognized in Diagnostics & Disease Treatment Category Showcasing BioPharma Collaborative Excellence

EMERYVILLE, Calif., April 25, 2016 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, is pleased to announce it has been named a Gold Edison Award winner for its collaborative development work on production of artemisinin for life-saving artemisinin combination therapies (ACTs), the World Health Organization’s recommended first-line treatment for malaria. The Edison Awards, named after inventor Thomas Edison, are among the most prestigious accolades a company can receive and honor new product and service development, marketing, human-centered design and innovation that are considered “game-changing.”

“Amyris is honored to be among the globally recognized business leaders to have received this prestigious award, which highlights our collaborative excellence in harnessing our advanced technology platform and innovation to help solve global problems,” said John Melo, Amyris President & CEO. “This showcases the hard work of our world-class scientists and the success in working with our partners.”

Continued Melo, “We are applying our platform beyond the development of artemisinin, and expect our platform to support and accelerate drug discovery for companies in the biopharma space where we are in active discussions with several potential partners.”

Advantaged Platform for Pharmaceutical Development

Amyris's advanced synthetic biology platform combines high-speed genomic engineering with high-performance screening and production scale-up, which provides a powerful alternative to support development and production of pharmaceutical precursors or ingredients such as artemisinic acid. By encoding microbes to efficiently produce molecules, Amyris has shown that its technology can help partners achieve cost-effective manufacturing of pure, high-quality ingredients very quickly. Amyris’s ability to manufacture natural and natural-like products also means that previously scarce or unavailable materials can be generated for all phases of pharmaceutical development – from screening for target functionality, through clinical trials, all the way to full-scale production.

Edison Award nominees are judged by more than 3,000 senior business executives and academics from across the nation whose votes acknowledge the Finalists’ success in meeting the award’s stringent criteria of quality. The Edison Awards is a program conducted by Edison Universe, a 501(c)(3) charitable organization dedicated to fostering future innovators. For more information about the Edison Awards, Edison Universe and a list of past winners, visit

About Amyris

Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients and consumer products. The company is delivering its No Compromise® products in focused markets, including specialty and performance chemicals, fragrance ingredients, and cosmetic emollients. More information about the company is available at

Forward-Looking Statements
This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as use of the Amyris technology platform beyond production of artemisinin to support and accelerate drug discovery for companies in the biopharma space, ability of Amyris technology to generate material for all phases of pharmaceutical development, prospects for collaborations with pharmaceutical companies, and other potential benefits Amyris can provide to prospective pharmaceutical collaboration partners), that involve risks and uncertainties. These statements are based on management’s current expectations and actual results and future events may differ materially due to risks and uncertainties, including  the company's liquidity and ability to fund operating and capital expenses, Amyris's reliance on third parties to achieve its goals, timing and execution risks associated with development and manufacturing, potential delays or failures in development, production and commercialization of products, and other risks detailed in the “Risk Factors” section of Amyris’s annual report on Form 10-K filed on March 30, 2016. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

Amyris and the Amyris logo are registered trademarks of Amyris, Inc. All other trademarks are the property of their respective owners.


Contact Data